Company Number: 14458711

Analysis Date: 2025-07-29 12:32 UTC

1. Credit Opinion: CONDITIONAL APPROVAL

Titan Pharma Ltd is a recently incorporated SME in the human health activities sector with a very limited trading history. The company shows a significant investment in fixed assets (notably goodwill of £534k and tangible assets of £175k) funded largely through long-term borrowings (£672k) and other creditors (£250k). Although currently solvent with net assets of £19k, the company has a negative net working capital position (-£16.8k) which highlights potential short-term liquidity risks. The absence of an income statement and limited operational history means cash flow sustainability and profitability are uncertain. Approval for credit should be conditional on receiving updated management accounts demonstrating improving cash flow and coverage of short-term liabilities.

2. Financial Strength:

The balance sheet reveals a strong asset base primarily driven by intangible assets (goodwill from acquisition) and tangible fixed assets. However, these assets are heavily leveraged with £671k of long-term debt and a further £265k of current liabilities exceeding current assets, resulting in working capital deficiency. Shareholders’ funds are minimal (£19k), indicating low equity cushion. The capital structure suggests high financial risk, reliant on servicing substantial debt. The company is classified as small exemption filing, which limits detail on profitability and cash generation.

3. Cash Flow Assessment:

Cash at bank is modest at £52k, an improvement from £7 in prior year, but still low relative to current liabilities. Debtors of £186k indicate some receivables to convert to cash, though their collectability and timing are unknown. The company’s negative net current assets indicate a shortfall to meet immediate liabilities, raising concerns about liquidity management. The presence of bank loans and overdrafts (£21.5k current portion) suggests some access to short-term financing, but reliance on external funding is high. Without an income statement or cash flow statement, it is difficult to assess operational cash flow, underscoring the need for ongoing monitoring.

4. Monitoring Points:

• Monthly/quarterly cash flow and management accounts to assess liquidity trends and debt servicing capability.
• Receivables aging and collection efficiency to ensure timely cash inflows.
• Debt covenant compliance and any changes in creditor terms.
• Progress on amortisation of goodwill and depreciation affecting earnings quality.
• Any capital injections or equity strengthening to improve solvency.
• Directors’ operational plans and strategy to achieve profitability given investment in assets.

Executive Summary:

Titan Pharma Ltd is a newly established company with a substantial investment in goodwill and fixed assets funded mainly by debt, resulting in weak working capital and minimal equity. While the business is solvent, limited trading history and negative net current assets present liquidity risks. Credit approval is recommended conditionally, pending evidence of improving cash flow and operational performance to support debt obligations.